Abstract: The present invention relates to a pharmaceutical composition comprising a therapeutically effective dose of Lenvatinib mesylate having sodium wherein the weight ratio of Lenvatinib mesylate to sodium carbonates ranges from 1:1.5 to 1:5.

Abstract: The instant disclosure provides a capsule composition comprising pullulan, a setting system and a surfactant system that is a sucroglyceride or a sugar fatty acid ester, and methods for making such capsules.

Abstract: The present disclosure provides a pyraclostrobin microcapsule based on sodium alginate, which is prepared by mixing pyraclostrobin original drug dissolved in ethyl acetate, 1% aqueous sodium alginate solution, and 5% aqueous calcium carbonate solution at 25° C., and mixing the mixed solution with liquid paraffin containing 10% emulsifier A-110, maintaining a shear rate of 1000 r/min to emulsify for 10 min; using 87.5 mmol/L glacial acetic acid to reduce the pH of the mixed phase, such that the cross-linking reaction between ions can be formed into microcapsules; finally using pH 4.5 acetate buffer to wash and separate the microcapsule slurry, and then centrifuging and freeze-drying to prepare the pyraclostrobin SA microcapsules. The microcapsules prepared by the present disclosure have excellent formulation performance and can be used for the control of Fusarium pseudograminearum.

Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.

Abstract: The present disclosure provides an siRNA nanocapsule and a preparation method and use thereof, relating to the technical field of biomedical engineering. The siRNA nanocapsule provided in the present disclosure includes siRNA and a shell encapsulating the siRNA and polymerized by a monomer A and a monomer B. The monomer A has a double bond at one end, and is electrostatically bound with the siRNA, and the monomer B includes molecules for improving tumor microenvironment sensitivity. The siRNA nanocapsule provided in the present disclosure is suitable for a wide range of clinical applications.

Abstract: An oral colon-targeted delivery system is described, which includes a bacterial flora sensitive layer which contains polysaccharides and covers the exterior of active ingredients, a pH sensitive layer which contains any polymer composition dissolved under the condition of pH?7 and covers the exterior of the bacterial flora sensitive layer. A preparation method and applications of the delivery system are also described. According to the oral colon-targeted delivery system combined with the pH sensitive and bacterial flora sensitive mechanisms, the selective dissolution and release of active ingredients in the colon site are effectively improved by using double-layer protection so that the therapeutic or diagnostic effect is enhanced, and the application prospect is broad.

Abstract: The present invention concerns compositions comprising at least one niclosamide compound, such as niclosamide or a pharmaceutically acceptable salt thereof, and at least one permeability enhancer, such as glycerol or dimethylpalmityl-ammonio propanesulfonate (PPS), and their use of such compositions as niclosamide agents. Advantageously, the niclosamide compound is capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 cell membrane in the absence of the permeability enhancer. Compositions, including oral dosage forms, and methods for delivering niclosamide compounds, such as for treatment or prevention of human coronavirus infections, are also provided.

Abstract: There are provided an enteric coating composition having an excellent film-forming property, being capable of forming a film at a lower temperature than conventional compositions, and/or being capable of avoiding decomposition of a drug due to a high temperature and operational troubles due to or nozzle clogging; and others. More specifically, there are provided an enteric coating composition containing hypromellose acetate succinate having a molar substitution of hydroxypropoxy groups of 0.40 or more, and water; a method for producing a solid preparation including steps of coating a drug-containing core with the enteric coating composition to obtain a coating layer, and drying the coating layer; and a solid preparation containing a drug-containing core, and a coating layer directly or indirectly on the core, the coating layer containing a hypromellose acetate succinate having a molar substitution of hydroxypropoxy groups of 0.40 or more.

Abstract: The present invention is related to a composition comprising at least one bile acid; at least one fatty acid or salt thereof, calcium, and vitamin D, for use as a medicament, and especially in inducing expression of vitamin D-receptor co-activator Hsp90? for increasing vitamin D-induced calcium uptake in a mammal. The invention is also related to a dietary or nutritional supplement comprising a composition as described above and comprising additionally conventional components for dietary or nutritional supplements.

Abstract: The present invention relates to a novel pharmaceutical use of bromide, i.e. the treatment of autism spectral disorder (ASD).

Abstract: A dispersion solution including a solvent which contains fine particles of a copper compound, a stabilizer, a fatty acid, a fatty acid ester of the fatty acid, and a polycarboxylic acid. The fine particles of the copper compound having antiviral property are homogeneously dispersed in the dispersion medium maintaining stability over extended periods of time.

Abstract: Orally administrable pharmaceutical compositions, methods of administration, and methods of making the same are provided. The pharmaceutical compositions provide abuse deterrent properties.

Abstract: The present invention relates to a process for producing a composition comprising an aqueous medium and, disposed in the aqueous medium, a first volume of a first hydrogel, which process comprises: (i) providing a composition comprising a first hydrophobic medium and, disposed in the first hydrophobic medium, a first volume of a first hydrogel; (ii) disposing a volume of an aqueous composition comprising a hydrogel compound around the first volume of the first hydrogel; (iii) allowing the aqueous composition comprising the hydrogel compound to form a gel and thereby forming a hydrogel object, which hydrogel object comprises the first volume of the first hydrogel and a second volume of a second hydrogel, which second volume of the second hydrogel is disposed around the first volume of the first hydrogel; and (iv) transferring the hydrogel object from the first hydrophobic medium to an aqueous medium and thereby producing the composition comprising the aqueous medium and, disposed in the aqueous medium, the fir

Abstract: The present disclosure belongs to the technical field of soft capsules, and particularly relates to a plant soft capsule and a preparation method and application thereof. The plant soft capsule with excellent performance is prepared from carrageenan, starch, a plasticizer and water by controlling the weight-average molecular weight of the carrageenan to be 1.2×106 to 2.0×106. Compared with a plant soft capsule in the existing technology, the plant soft capsule of the present discourse has lower production cost, and the product quality meets the requirements of gelatin soft capsules; and on the premise of high production efficiency, a low oil leakage rate is achieved, and the rupture time meets United States Pharmacopoeia (USP) standards. The plant soft capsule prepared according to the present disclosure can be filled with an active component as a content and used for preparation of a plurality of drugs, functional food or dietary nutritional supplements.

Abstract: The present invention relates to an orally-administered gene carrier and a use thereof, and more specifically, to: an oral gene carrier comprising, at the C-terminus of an immunoglobulin Fc region, a linker formed from cationic arginine and enabling the condensation of an anionic gene; and an oral composition for preventing, ameliorating or treating metabolic diseases, the composition comprising the gene carrier and the GLP-1 gene as active ingredients. The gene carrier, according to the present invention, may be usefully employed as an orally-administered carrier for various genes, and especially, is expected to be usable for preventing, ameliorating or treating metabolic diseases, such as diabetes and obesity, by effectively transferring the GLP-1 gene.

Abstract: The present disclosure provides compositions comprising a supercritical rosemary extract and a lipid system comprising raffish liver oil or the product of an enzymatic or chemical glycerolysis processing of ratfish liver oil. The present disclosure also provides use of said compositions for immunotherapy potentiators or adjuvants for patients with cancer or immunological disorders; treatment of autoimmune-based immunological disorder selected from the group consisting of: rheumatoid arthritis, type I diabetes, psoriasis, celiac disease and multiple sclerosis; treatment of tumor growth, chronic lymphocytic choriomeningitis virus infection, hepatitis (B and C) virus infection, or human immunodeficiency virus infection; or prevention of kidney damage.

Abstract: The present invention relates to transparent disc-shaped microparticles having polydopamine-modified surfaces and cell culture using the same. When the disc-shaped microparticles coated with polydopamine according to the present invention are used in cell culture, cell adhesive properties are improved and an inverted microscope may be employed to observe cells, which are major advantages when compared to conventional spherical microcarriers.

Abstract: Aspects of the present invention are directed to an oral dosage form comprising a core containing one more active ingredients and a fast-release exterior coating. The fast release exterior coating includes a water soluble polymer; a saccharide or sugar alcohol, or a combination thereof, and a flavoring. The flavoring may be a warming sensate that is released in the oral cavity of the user after inserting the dosage form in his or her mouth.

Abstract: Provided is a pharmaceutical composition and food composition for treating or preventing a skin disease caused by abnormal growth of a skin bacterium or infection with a pathogenic microorganism. A composition comprising a lactic acid bacterium as an active ingredient, for suppressing bacterial abnormal growth, or preventing or ameliorating deterioration of skin condition caused by a bacterial abnormal growth, by oral intake thereof.

Abstract: The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and a milk thistle extract or powder. The invention also relates to the combination of a sulforaphane or a derivative thereof and a milk thistle extract or powder. The invention also relates to the combination of a broccoli extract or powder and a milk thistle extract or powder. The invention provides compositions and methods relating to these combinations.

Abstract: A modified transferrin DNA binding domain. The transferrin is lactotransferrin (LTF), serotransferrin (TF), melanotransferrin (MTF) or ovotransferrin (OTF), and the N terminal of each transferrin has one homologous DNA binding domain, wherein the 10th site and 20th site of the DNA binding domain are C; and the amino acid sequence of the modified transferrin DNA binding domain is as follows: C in the 10th site and 20th? site is replaced by other amino acids so that no disulfide bond can be formed. The present invention also discloses a recombinant DNA polymerase and a preparation method thereof. The preparation method comprises the step of coupling the modified transferrin DNA binding domain with a DNA polymerase. The present invention also discloses a PCR test kit containing the recombinant DNA polymerase.

Abstract: Microbiota restoration therapy (MRT) compositions (e.g., oral MRT compositions) and methods for manufacturing MRT compositions are disclosed. An example method for manufacturing an MRT composition may include collecting a stool sample, purifying the stool sample to form a purified sample, stabilizing the purified sample to form a stabilized sample, converting the stabilized sample to a solid, adding one or more additives and/or excipients to the solid to form a treatment composition, and encapsulating the treatment composition.

Abstract: The present invention relates to sanglifehrin macrocyclic analogues according to Formula (I), particularly for use in treatment of cancer, especially liver cancer.

Abstract: The present invention relates to a formulation for the controlled release of active ingredients after the passage of the ileo-cecal-valve, comprising one or more active ingredients or one or more active ingredient containing cores (W), enveloped by one or more envelopments (C), which are dissoluble or permeable above an individual defined pH value and are dissoluble or permeable below another individual defined pH value, again enveloped by an envelopment (E), which is dissoluble or permeable above still another individual defined pH value.

Abstract: Disclosed herein are self-emulsifying compositions and formulations of Dimdolylmethane (“DIM”) and certain derivatives of DIM, their uses and methods of making. In particular, the disclosed compositions comprise a DIM-related indole as an active agent and a carrier, wherein the carrier comprises a solvent, one or more surfactants with an HLB of greater than 7, and one or more co-surfactants with an HLB equal to or less than 7. In certain aspects of the invention, the compositions disclosed herein show improved bioavailability.

Abstract: The present invention relates to a formulation for the controlled release of active ingredients after the passage of the ileo-cecal-valve, comprising one or more active ingredients or one or more active ingredient containing cores (W), enveloped by one or more envelopments (C), which are dissoluble or permeable above an individual defined pH value and are dissoluble or permeable below another individual defined pH value, again enveloped by an envelopment (E), which is dissoluble or permeable above still another individual defined pH value.

Abstract: Disclosed a pregabalin-containing, high swellable, oral sustained-release triple layer tablet suitable for administration once daily.

Abstract: The invention provides oral vaccine formulations which deliver an antigen in the vicinity of the distal ileum and the area of the ileal Brake and/or the appendix. These vaccines are useful in the treatment and/or prevention of variety of disorders, including viral and bacterial infections and cancers. Related methods of treatment which use the oral vaccine formulations of the invention are also provided.

Abstract: A novel adjuvant composition is provided that is excellent in safety and convenience as compared to the conventional adjuvant such as Alum. An adjuvant composition comprising citrullines, which are water soluble substance present in the living body, and/or a salt thereof; a vaccine composition comprising said adjuvant composition and an antigen; a process for preparing said adjuvant composition and said vaccine composition; and a method for administering said adjuvant composition and said vaccine composition are provided.

Abstract: Uronate-containing polysaccharide hydrogels that can be photo-patterned are described. The method involves forming a hydrogel and imetal-coordinating it with a reducible metallic cation and exposing the hydrogel to light in a desired pattern. The exposure to light reduces the metallic cation and results in an irreversible change in the elastic moduli and pore size of the irradiated portions of the patterned hydrogel. The method aha the benefit of allowing the user to produce such a hydrogel in any pattern desired. Patterned hydrogels and cell substrates formed by this method are also described.

Abstract: Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.

Abstract: Disclosed are stem cells having a thin multilayer structure, a method of preparing the same, and use thereof for cytotherapy. In accordance with the present invention, stem cells with a thin multilayer structure having improved stability and controlled multifunctionality are provided. A method of preparing the stem cells having the thin multilayer structure according to the present invention is very simple, and thus, the stem cells having the thin multilayer structure can be produced at low cost and high efficiency. Therefore, the stem cells having the thin multilayer structure prepared according to the present invention are very useful as a stem cell therapy agent for treating various diseases.

Abstract: Compositions and methods for inhibiting, treating, and/or preventing fatty acid metabolism disorders, particularly fatty acid oxidation disorders, in a subject are provided.

Abstract: A multi-point light-delivering device, comprising a waveguide carrying light along a longitudinal axis and including multiple optical windows, through which the carried light is out-coupled from the waveguide. The waveguide comprises a tapered region along which the optical windows are distributed, wherein each optical window out-couples a specific subset of propagating modes of the carried light, to which the optical window is matched.

Abstract: The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of breast cancer and other breast diseases and diseases susceptible to endoxifen. In particular, the compositions of the present invention include liposomes, complexes, vesicles, emulsions, micelles and mixed micelles of endoxifen in which the compositions further contain any of a variety of neutral or charged lipids and desirably, cholesterol and cholesterol derivatives, sterols, Z- and E-guggulsterones, phospholipids, fatty acids, vitamin D, and vitamin E. The present invention also provides methods of preparing endoxifen. The present invention provides methods for treating and preventing breast cancer and other breast related diseases by administrating novel formulations or compositions comprising a therapeutically effective amount of endoxifen.

Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.

Abstract: A urine handling system capsule for releasing an oil mixture in the lumen of a urine handling system, the capsule comprising a capsule wall defining a space filled with an oil mixture, wherein the oil mixture comprises 90-100% of an oil selected from the group consisting of silicone fluids and mineral oils or a mixture thereof, and having a viscosity of at most 600 cSt, and wherein the capsule wall is made of a water-soluble material. A urine measurement system comprising an oil mixture arranged in the luminal space of the measurement system. A method for inhibiting impairment of functionality and measurement accuracy in a urine measurement system comprising applying an oil mixture to the inner surfaces of the urine measurement system. Use of an oil mixture in treatment of luminal surfaces of a urine handling system.

Abstract: The present invention relates to a solid pharmaceutical composition of temozolomide that has good and consistent flowability as a powder and taste masking and is readily dispersible in an aqueous solution suitable for oral administration, e.g., as a dry sprinkle. This permits patients and healthcare workers to accurately measure doses.

Abstract: Personal care compositions, such as oral medication compositions containing a flavor system comprising one or more coolants. The pleasant cool sensation provided by a coolant is enhanced in terms of quicker onset, greater intensity, impact or longer duration, which improves appeal and acceptability of the compositions to consumers.

Abstract: A method for improving the performance of fracturing processes in oil production fields may rely on polymer coated particles carried in the fracturing fluid. The particles may include heavy substrates, such as sand, ceramic sand, or the like coated with polymers selected to absorb water, increasing the area and volume to travel more readily with the flow of fluid without settling out, or allowing the substrate to settle out. Ultimately, the substrate may become lodged in the fissures formed by the pressure or hydraulic fracturing, resulting in propping open of the fissures for improved productivity.

Abstract: A process for making hemoglobin based oxygen carrier (HBOC) containing pharmaceutical composition suitable for oral delivery and the composition formed thereby are described. There are three exemplary composition configurations which include (1) hemoglobin-loaded nanoparticles solution, (2) enteric-coated hemoglobin capsules and (3) enteric-coated hemoglobin tablets. To facilitate the bioavailability and bio-compatibility of hemoglobin, intestinal absorption enhancers are added in each of the HBOC formulations. Protective layers ensure delivery of an intact hemoglobin structure in intestinal tract without degradation in the stomach. The HBOC formulations may be used for preventive or immediate treatment of high altitude syndrome (HAS) or for treatment of hypoxic conditions including blood loss, anemia, hypoxic cancerous tissue, and other oxygen-deprivation disorders.

Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Abstract: Disclosed is a pharmaceutical nitazoxanide composition comprising: (a) an immediate release fraction comprising nitazoxanide non-coated granules or non-granulated powder, and (b) a pH-dependent release fraction comprising granules of nitazoxanide coated with one or more polymers having a pH-dependent solubility.

Abstract: Personal care compositions, such as oral medication compositions containing a flavor system comprising one or more coolants. The pleasant cool sensation provided by a coolant is enhanced in terms of quicker onset, greater intensity, impact or longer duration, which improves appeal and acceptability of the compositions to consumers.

Abstract: The present disclosure provides pharmaceutical compositions of statins and polyunsaturated fatty acids (PUFAs), in which the statins are dissolved in the PUFAs, the PUFA species being present substantially in the free acid form. Also provided are oral unit dosage forms of the disclosed pharmaceutical compositions and methods of treating blood lipid disorders using the compositions and oral unit dosage forms.

Abstract: The present invention relates to a hydrogel matrix comprising cartilage-forming cells wherein alginate, chitosan and cartilage-forming cells are mixed and subsequently polymerized into beads.

Abstract: Methods for microfabricating composite materials and composite materials prepared there from are described herein. The sacrificial material can be etched or patterned to create a two-dimensional and/or three-dimensional sacrificial material structure. The resulting sacrificial material structure can be embedded in one or more embedding materials. The sacrificial material(s) are materials whose solubility can be altered by application of a stimulus typically pH, and/or temperature, light, pH, pressure, presence of absence of ions, and combinations thereof. The embedding materials can contain one or more additives that modify one or more properties of the embedding materials, such as degradation properties, porosity, mechanical properties, viscosity, conductive properties, and combinations thereof. The composite materials can be used in tissue engineering, drug screening, toxin detection, drug delivery, filtrations, bioseparations, and as microfluidic devices for fluid mixing and structural repair.

Abstract: Methods, devices and arrays for measuring a change in zeta-potential of a surface indicative of a binding event are provided. Pharmacologically active compounds and delivery systems for active pharmaceutical ingredients determined to be pharmacologically active or optimized for pharmacological activity or determined to be useful for delivery of the active pharmaceutical ingredient to a target via measurement of a change in zeta-potential of the compound, ingredient or delivery system are also provided.

Abstract: The invention relates generally to methods of making formulations for delivering biological agents to a patient. In one aspect, proliposomal drug-delivery systems for medicaments are provided. In another aspect, coated proliposomal formulations for poorly water soluble drugs, and methods for making the same, are provided. Certain embodiments of the present invention provide enhanced stability and bioavailability for pharmaceutical formulations.

Abstract: A composition for treating inflammation and pain, including a hydrogen-generating compound in an amount that increases the amount of hydrogen in an individual and has an anti-inflammatory effect. A composition for treating inflammation and pain, including synergistically effective amounts of pregabalin and lactulose. A method of treating inflammation and pain, by administering a composition comprising a hydrogen-generating compound to an individual in an amount that increases the amount of hydrogen in the individual and has an anti-inflammatory effect.